Objective: The aim of this study was to identify the range and frequency of patientreported barriers and facilitators to antiretroviral treatment (ART) adherence in subSaharan Africa (SSA).
Introduction
Nearly 25 million people, 70% of all those living with HIV globally, live in countries in sub-Saharan Africa (SSA) [1] . HIV is a debilitating disease; however, antiretroviral treatment (ART) helps promote effective viral suppression, reduces the risk of transmission and prevents death [2, 3] . To ensure positive treatment outcomes, high levels of ART adherence (80-95%) are necessary depending on the regime potency [4] [5] [6] ;
All databases were searched from 2005 to 24 May 2016 to investigate the research published since the review by Mills et al. [3] . All records were downloaded into ENDNOTE (X7.4).
Hand-searching, web-searching and forward citation searching were conducted to find other relevant published and unpublished studies. Abstracts from the following international conferences were searched: International AIDS Society (IAS; [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] [2015] , Conference on Retroviruses and Opportunistic Infections (CROI; 2014, 2016), AIDS Impact (2009) (2010) (2011) (2012) (2013) (2014) (2015) and International AIDS Conference (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) . For all potentially relevant abstracts, if no published article was found, the authors were contacted for more details if possible. Reference lists of included articles and systematic reviews were searched. Searches in Google Scholar were conducted using search terms such as 'adherence', 'HIV' and 'Sub-Saharan Africa'. Forward tracking of the review by Mills et al. [3] was also performed in the Web of Science database.
Study selection N.C. reviewed all the titles and abstracts of each record to assess potential relevance and M.Ah. examined a random sample (10%) and a concordance rate was measured. Acceptable concordance was predefined as agreement on at least 90%, which is the same as other health reviews [13, 14] . N.C. reviewed the full text for any potentially relevant studies to assess eligibility. Eligible studies met the following criteria: based in SSA, original research, any language, qualitative study or quantitative survey and included an adult patient-reported barrier or facilitator to ART adherence. Studies were excluded if they only focused on initiation to ART in treatment-naive participants, only utilized a single dose of ART treatment, for example prophylaxis, only focused on Africans living in a non-SSA country or were only reviews.
Quality assessment N.C. completed quality assessment for all included studies. M.Ah. assessed a random sample of 30 (15 qualitative and 15 quantitative). The RATS (Relevance, Appropriateness, Transparency, Soundness) measure [15] was used to assess the qualitative studies and a measure developed by Hawker et al. [16] was used to assess the quantitative studies (see supplementary material for further details, http://links.lww.com/QAD/B44).
Duplicates excluded = 5218
Total number of records after duplicates excluded = 6065
Excluded based upon title and abstract = 5266 [80] , one used group sessions without more detail [168] , one used IDIs and life history and illness narratives [48] and one used digital stories [91] . Having a routine (9) Stigma and discrimination (68) ART packaging (7) Outside house or travelling (60) c Access to food and/or water (6) d Being busy (30) Carrying ART whilst out of the house (5) Run out of ART (26) Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
excluding medication collection and treatment-related factors (see Table 1 ). Due to the comparable themes, the barriers and facilitators will be described together.
Themes
There were several factors that impacted adherence related to finance as well as each patient's health provider. Within the finance theme, in particular not receiving financial help was a barrier, whereas receiving funds was a benefit. Across studies, the fifth most reported facilitator was having a good relationship with their health provider (n ¼ 22). The opposite was identified as a barrier, however, only by a few studies (n ¼ 5).
Four of the five most-reported barriers across all studies were classified into the medication-taking theme; forgetting (n ¼ 76), lack of access to adequate food (n ¼ 72), stigma and discrimination (n ¼ 68) and being outside the house or travelling (n ¼ 60). Some of these had comparable facilitators, including having reminders to take medication [which was the second most reported facilitator (n ¼ 55)], having access to food or water and carrying ART whilst out of the house, although the latter two were only identified by a small number of studies.
Interpersonal relationships included the first and fourth most reported facilitators [social support (n ¼ 60) and having disclosed their HIV status (n ¼ 26)]. Both of these included comparable barriers (e.g. lack of social support and HIV nondisclosure) indicating that an absence of these factors is a barrier to adherence.
Mental health and well-being was the only theme to include the same factor as both a barrier and facilitator, feeling better or healthier after ART treatment. This factor was the third most reported facilitator across studies (n ¼ 35), although 26 studies also reported it as a barrier. Another comparable barrier to feeling better was also reported (feeling sick or ill) indicating that the opposite can also hinder adherence. Feeling hopeless and being hopeful were both reported as comparable factors, although only reported in a few studies.
The patients' beliefs about HIV and treatments theme also included factors that acted as a barrier or facilitator. Both religious and traditional beliefs and treatments were indicated as a barrier to adhering to ART, whilst a patient's desire to take control of their health was a facilitator. Denial of one's own HIV status was reported as a barrier and had a comparable facilitator of accepting one's own HIV status, although these were reported by a small number of studies. Specific beliefs about ART also showed to have an impact on adherence. The belief in the benefit of ART was reported (n ¼ 20) as a facilitator, whereas believing ART will not work was reported as a barrier, but only by seven studies in comparison.
Both medication collection and treatment-related factors only included barriers. The latter theme included the fourth most reported barrier across studies, side effects (n ¼ 67). Erratic clinic drug supply and long waiting times were reported by the most studies as a barrier to ART adherence in the medication collection theme.
Discussion
Summary of evidence In this systematic review, a total of 43 patient-reported barriers and 30 facilitators to ART adherence were identified in 154 studies across 24 SSA countries. Barriers and facilitators to ART adherence included factors related to participants' physically taking their ART medication (e.g. unable to take their pills without adequate food or using reminders to remember to take their pills), factors that impacted participants' physical or mental health (e.g. feeling sick or feeling better after taking ART), factors related to participants' relationships with other people (e.g. nondisclosure of HIV status to others or social support), factors related to finance (e.g. lack of money for HIV care or free ART treatment), factors related to participants' health provider including all staff (e.g. experiencing negative treatment from clinic staff or having a good relationship with their health provider), beliefs around HIV and treatments for HIV (e.g. using traditional medicines or accepting own HIV status) and beliefs regarding ART (e.g. ART is harmful or ART is beneficial). Factors related to collecting medication at the clinic (e.g. long waiting times or erratic drug supply) and treatment-related factors (e.g. side effects or pill burden) were only reported as barriers to ART adherence. One factor was both a barrier and facilitator (e.g. feeling better after taking ART), which emphasizes medicationadhering behaviour is not universal and it is necessary to explore this individually. The most frequently identified barriers across studies and methodologies were forgetting, lack of access to adequate food, stigma and discrimination, side effects and being outside the house or travelling. The most frequently identified facilitators across studies and methods were social support, using reminders, feeling better or healthier after taking ART, disclosing their HIV status and having a good relationship with a health provider. This review helps identify the range and frequency of factors that impact ART adherence for patients within a variety of different settings in SSA.
Other systematic reviews have focused on specific types of adherence barriers, including geographic and transport-related barriers in SSA [171] , food insecurity [172] and depression and alcohol use in SSA [173] . These reviews are useful because they go in-depth into one type of barrier and they may focus on HIV outcomes other than adherence [171] ; however, this review is necessary to
give an overview of the many factors that affect ART adherence in SSA.
Frequency across studies does not necessarily equate with importance for individuals; therefore, the most reported factors may not have the greatest impact upon adherence. Unfortunately, the low number of studies that included the nonadherent within-study frequencies means it is difficult to compare the impact of these on adherence.
Future studies should include these to allow researchers to ascertain not only the range of factors that affect adherence but also the impact of each.
This review identified 26 barriers that were not previously reported in SSA in the previous systematic review [3] , including traditional medicines, religious beliefs or treatments, lack of access to food and sharing medication. These need to be acknowledged when working with people living with HIV in SSA. The five most frequently reported facilitators were included in the previous review [3] , showing that there is similarity between patients in HIC and LMIC; however, several others were identified that had not been previously noted, for example financial aid, access to food and water and religious beliefs. This further confirms that there are factors that may be more applicable to LMIC that therefore need particular consideration when designing interventions to improve ART adherence.
Understanding and being aware of these are important for policy makers, researchers and health professionals. Although patients denied missing ART doses to their health professional, if a barrier measure was used, patients would then reveal nonadherence by indicating the barriers that prevent them from adhering [174] . Having a list of barriers that are applicable to the context is essential. There are some differences between HIC and LMIC and this should be reflected in the provisions available for patients. Although general and HIV-specific measures for barriers to adherence do currently exist [175] [176] [177] [178] [179] , none encompass the wide range of reasons identified in this review. Developing or adapting a measure that can be utilized by health professionals in SSA is necessary. In particular, the most commonly used selfreport HIV adherence measure [180] (Adult AIDS Care Trials Group [AACTG]) includes a 'reasons for nonadherence' subscale [175] that needs to be adapted if used in SSA to include all relevant factors. To our knowledge, there is not a similar measure for facilitators and research needs to explore whether assessing the facilitators may be equally as helpful as the barriers to reach the level of desired adherence.
Immediate treatment initiation after diagnosis has been shown to have more positive HIV outcomes than later [181, 182] and thus may become the recommended start date globally. There are debates in the literature about the practicalities associated with immediate ART initiation [183] , including increased burden on the healthcare system, increased frequency of risk behaviours when receiving ART and ethical issues such as resource allocation in low-resource settings [183] . The impact of certain barriers may increase, such as the factors associated with healthcare; therefore, the need to enhance the facilitators will become greater.
Future research needs to help identify the barriers and facilitators that have the greatest impact on adherence and help develop interventions based upon these. Within SSA, there have been several interventions focused on helping participants remember their medication, whereas less have focused on lack of food or stigma [184] .
Research needs to explore whether these other interventions would have a greater influence on adherence. In addition, the focus on adherence interventions in SSA has often been observational and more randomized control trials (RCTs) are required [184] .
Limitations
Although efforts were made to include all eligible studies, it is possible that not all studies exploring barriers and facilitators to ART adherence in SSA were included, as research from resource-constrained settings may be less likely to be published or not indexed in the major databases [185] . The studies are not easily compared due to the heterogeneity of how factors and adherence were measured. There was a great variety of within-study frequency measurement; therefore, only studies that included the frequency of reporting within nonadherent participants were included. Also, some studies combined separate factors into one, so it was not possible to extract the individual factors. The quality of the studies seemed generally fair; however, there were areas of poor quality. As two measures were utilized in quality assessment, it is not easy to compare the quality across both qualitative and quantitative studies.
The majority of the qualitative studies identified both barriers and facilitators, whereas the majority of the quantitative studies only identified barriers. This bias may have prevented certain facilitators from being identified. Barrier measures or adapted versions [175, 177, [186] [187] [188] [189] were utilized in some surveys that may have caused certain barriers to be reported more frequently; however, other important barriers may have been missed because they were not included.
Conclusion
This review highlights the range and frequency of barriers and facilitators that affect ART adherence in HIV adult patients in SSA. Research needs to help identify which factors have the greatest impact on adherence and develop interventions accordingly. Measures need to be developed or adapted for SSA to include all the relevant factors. Interventions need to be developed that aim to reduce the barriers and enhance the facilitators. By understanding
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and being able to identify what hurdles a patient experiences and how certain aspects may encourage them to adhere, the focus is now on using this information to help patients achieve optimum ART outcomes.
